Anixa Biosciences Inc ANIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
-
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
-
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
-
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
-
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Trading Information
- Previous Close Price
- $2.84
- Day Range
- $2.66–2.84
- 52-Week Range
- $2.32–5.46
- Bid/Ask
- $2.65 / $2.82
- Shares Outstanding
- 34.76M
- Market Cap
- $92.82M
- Volume/Avg
- 175,823 / 300,442
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.anixa.com
Valuation
|
Metric
|
ANIX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANIX
|
|---|---|
Quick Ratio | 7.94 |
Current Ratio | 8.54 |
Interest Coverage | — |
Quick Ratio
ANIX
Profitability
|
Metric
|
ANIX
|
|---|---|
Return on Assets (Normalized) | −47.95% |
Return on Equity (Normalized) | −49.93% |
Return on Invested Capital (Normalized) | −57.19% |
Return on Assets
ANIX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?<>?>&# | LOCK|N#jx | $123B | |||
| Moderna Inc
MRNA
| LOCK|t?NSMC | LOCK|$#< | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Kw^^>n% | LOCK|G>@N | $78B | |||
| argenx SE ADR
ARGX
| LOCK|>p>?DN% | LOCK|xQ> | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>yVb## | LOCK|XDY | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|yN$G&#q | LOCK|m<>n | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|GjVp!%f? | LOCK|VqF^T | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|tCyfG$ | LOCK|y< | $22B | |||
| Incyte Corp
INCY
| LOCK|s&zL!Z | LOCK|&v | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Bn^T&VG | LOCK|cs | $14B |
United States